NL-OMON23734
Recruiting
Not Applicable
Incorporation of Multimodality Magnetic Resonance Imaging in the PRIAS study.
C.M.A. Hoeks, MDDepartment of Radiology Radboud University Nijmegen Medical Centre0 sites80 target enrollmentTBD
Conditionsprostate cancer, prostaatkanker
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- prostate cancer, prostaatkanker
- Sponsor
- C.M.A. Hoeks, MDDepartment of Radiology Radboud University Nijmegen Medical Centre
- Enrollment
- 80
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
/A
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Histologically proven adenocarcinoma of the prostate;
- •2\. PSA ¡Ü 10 ng/ml and PSA density \<0\.2 ng/ml/ml;
Exclusion Criteria
- •1\. Patients with known contradictions to MRI;
- •2\. Patients with known contra\-indications to Gadolinium based contrast agents;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Incorporation of Multimodality Magnetic Resonance Imaging in the PRIAS studyprostate cancer prostate carcinoma10036958NL-OMON33150niversitair Medisch Centrum Sint Radboud80
Completed
Phase 2
A study looking at the use of multiparametric Magnetic Resonance Imaging (MRI) and Positron Emission Tomography - Computed Tomography (PET-CT) to evaluate radiological changes after lung stereotactic ablative radiotherapy (SABR).on small cell lung cancer (NSCLC)Oligometastatic disease involving lungNon small cell lung cancer (NSCLC)Cancer - Lung - Non small cellCancer - Other cancer typesACTRN12616000801415iverpool Hospital23
Recruiting
Not Applicable
Quantitative MRI Assessment of Breast Cancer Therapy ResponseBreast CancerNCT05704062Corewell Health East135
Completed
Not Applicable
MRI in Active Surveillance of Prostate CancerProstate CancerNCT02326246Aarhus University Hospital Skejby85
Completed
Not Applicable
Radiation Therapy Planning Techniques in Reducing Damage to Normal Tissue in Women Undergoing Breast-Conserving Surgery for Ductal Carcinoma of the BreastBreast CancerNCT00602628Royal Marsden NHS Foundation Trust60